Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

The company says preclinical trials demonstrate its signature molecule can help prevent cell damage that can lead to ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...